1800-272-662
Shopping Cart 0
countryflagAU
Login

Paradigm Biopharmaceuticals Ltd

Healthcare AU PAR

0.26AUD
0.01(4.00%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.240.27
LowHigh

52 Week Range

0.240.48
LowHigh

Fundamentals

  • Previous Close 0.25
  • Market Cap109.81M
  • Volume894342
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-38.67086M
  • Revenue TTM0.00845M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00207M
  • Diluted EPS TTM-0.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -25.30384M -58.65300M -51.91001M -39.24958M -34.29718M
Minority interest - - - - -
Net income -18.77075M -58.65300M -51.91001M -39.27822M -43.04688M
Selling general administrative 5.58M 6.22M 6.56M 7.93M 8.75M
Selling and marketing expenses - 0.55M - - -
Gross profit -0.01989M 0.06M 0.03M -0.06453M -0.07859M
Reconciled depreciation - 0.15M - 0.06M 0.21M
Ebit -25.29676M -64.68574M -60.03851M -39.22095M -34.25946M
Ebitda -25.24534M -64.53900M -51.89360M -39.15998M -34.04940M
Depreciation and amortization 0.05M 0.15M - 0.06M 0.21M
Non operating income net other - - - - -
Operating income -22.88621M -65.19300M -51.89360M -39.22095M -34.25946M
Other operating expenses 22.94M 65.11M 60.09M 48.07M 43.41M
Interest expense 0.00708M 0.01M 0.02M 0.03M 0.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00167M 0.41M 0.41M 0.05M 0.04M
Net interest income - 0.39M 1.39M 0.02M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.53309M -5.96945M - 0.03M 8.75M
Total revenue 0.05M 0.07M 0.05M 0.08M 0.02M
Total operating expenses 22.87M 65.10M 60.07M 47.93M 43.31M
Cost of revenue 0.07M 0.00899M 0.02M 0.14M 0.10M
Total other income expense net -2.41763M 6.54M 6.74M -0.02863M -0.03772M
Discontinued operations - - - - -
Net income from continuing ops - -58.65319M -51.91001M -39.24958M -34.29718M
Net income applicable to common shares -18.77075M -58.65319M -51.91001M -39.24958M -34.29718M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 24.57M 27.39M 67.07M 50.69M 84.79M
Intangible assets 0.41M - 2.95M 2.95M 2.95M
Earning assets - - - - -
Other current assets 0.94M 1.30M - 0.78M 1.43M
Total liab 3.39M 3.58M 13.39M 8.38M 6.52M
Total stockholder equity 21.18M 23.81M 53.68M 42.31M 78.27M
Deferred long term liab - - - - -
Other current liab 0.49M 0.42M 0.78M 0.59M 0.67M
Common stock 253.23M 238.11M 209.83M 147.19M 146.99M
Capital stock - - 209.83M 147.19M 146.99M
Retained earnings -235.94898M -220.73014M -163.51401M -114.01554M -75.22823M
Other liab - - 0.11M 0.08M 0.11M
Good will - - - - -
Other assets - 0.00000M - 0.00000M 0.10M
Cash 16.82M 17.82M 56.33M 39.67M 71.03M
Cash and equivalents - - - - -
Total current liabilities 3.23M 3.36M 13.04M 7.83M 5.79M
Current deferred revenue - - - - -
Net debt -16.81264M -17.58150M -55.99142M -39.05774M -70.28314M
Short term debt 0.00548M 0.12M 0.10M 0.15M 0.13M
Short long term debt - - - - -
Short long term debt total 0.00548M 0.24M 0.34M 0.62M 0.75M
Other stockholder equity - - -0.42878M 9.13M 6.51M
Property plant equipment - - 0.34M 0.57M 0.76M
Total current assets 24.13M 24.25M 63.79M 47.17M 80.98M
Long term investments - - - - 0.10M
Net tangible assets - - 50.73M 39.37M 75.33M
Short term investments - 0.05M 0.05M 0.05M 0.05M
Net receivables 6.37M 5.08M 6.81M 6.72M 8.51M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.73M 2.82M 12.16M 7.09M 4.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.90M 6.42M 7.36M 9.13M 6.51M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 2.95M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.44M 3.14M 3.28M 3.52M 3.81M
Capital lease obligations - - 0.34M 0.62M 0.75M
Long term debt total - - 0.14M 0.37M 0.62M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - - - 0.70M
Change to liabilities - - 5.07M 2.10M 2.20M
Total cashflows from investing activities 0.05M - 0.00000M 0.00000M 0.67M
Net borrowings - - -0.10449M -0.13517M -0.12185M
Total cash from financing activities 14.99M 28.18M 62.53M 0.07M 1.00M
Change to operating activities - - -0.10277M 0.54M -0.88882M
Net income -18.77075M -58.65319M -51.91001M -39.27822M -34.33491M
Change in cash -1.00270M -38.51226M 16.66M -31.36057M -32.88726M
Begin period cash flow 17.82M 56.33M 39.67M 71.03M 103.92M
End period cash flow 16.82M 17.82M 56.33M 39.67M 71.03M
Total cash from operating activities -15.99321M -65.94467M -45.18628M -39.21725M -34.92948M
Issuance of capital stock - 30.12M 65.99M - 1.02M
Depreciation 0.05M 0.15M 0.15M 0.06M 0.21M
Other cashflows from investing activities 0.05M -65.94467M 0.00000M 0.00000M 0.70M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.30785M 1.29M 0.36M 1.79M -5.04870M
Sale purchase of stock 16.00M -1.83761M -3.76487M 0.00000M 1.02M
Other cashflows from financing activities -0.12544M -0.10233M 0.31M 0.07M -0.01817M
Change to netincome - - 1.24M 2.41M 2.89M
Capital expenditures 0.00001M 65.94M 0.00000M 0.00000M 0.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.10M -8.68498M 0.95M 0.05M 0.26M
Stock based compensation - 1.20M - - -
Other non cash items 2.63M 1.25M - 39.22M 34.09M
Free cash flow -15.99322M -65.94467M -45.18628M -39.21725M -34.96112M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PAR
Paradigm Biopharmaceuticals Ltd		 0.01 4.00% 0.26 - 8.12 12995.69 19.04 1798.27 -6.7826
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Paradigm Biopharmaceuticals Ltd

500 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Exec. Chairman 1959
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Exec. Director 1957
Mr. Justin Cahill Chief Financial Officer NA
Dr. Ravi Krishnan Chief Scientific Officer NA
Mr. Simon White Director of Investor Relations NA
Dr. Michael Imperiale Global Head of Drug Safety & MPS NA
Ms. Beverley Huttmann Commercial Head NA
Ms. Michelle Coffey Global Head of Regulatory Affairs NA
Dr. Mukesh Ahuja Global Clinical Head of OA NA
Mr. Marco Polizzi Exec. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.